A 4-Week, Double-Blind, Placebo-Controlled, Parallel-Group, Fixed Dosage Study to Evaluate the Efficacy and Safety of Armodafinil as Adjunctive Therapy to Olanzapine in Adults with Cognitive Deficits Associated with Schizophrenia